OpenAI's new AI model, GPT-6 Astra, has achieved a perfect score on South Korea's CSAT exam, outperforming previous models like GPT-5.6, Claude, and Gemini in efficiency. Separately, an AI-designed drug developed by Insilico Medicine, rentosertib, has shown promising results in reducing biological age markers in patients during a clinical trial. Researchers are exploring whether this indicates an anti-aging effect or simply improved health due to disease treatment, with Nobel laureate Michael Levitt suggesting the consistent results across multiple aging clocks are significant. AI
IMPACT Sets new SOTA on standardized exams and suggests novel applications for AI in drug discovery and health.
RANK_REASON Frontier-lab model release with system card [lever_c_demoted from frontier_release: ic=1 ai=1.0]
Read on Email — The Neuron Daily →
- Anthropic
- Apple Inc.
- ByteDance
- Claude
- CSAT
- Gemini
- GPT-5.6
- GPT-6 Astra
- Insilico Medicine
- Meta
- Michael Levitt
- OpenAI
- rentosertib
- South Korea
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →
